Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810

Inclusion criteria

• Female participants of non-childbearing potential including non-pregnant, non-lactating, and either postmenopausal or surgically sterile for at least 45 days post procedure
• Body mass index (BMI) range 18.0 to 32.0 kilograms per square meter (kg/m^2), inclusive
• In good health, as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations
• Receive an explanation of the mandatory pharmacogenomics (PgX) component of the study

Exclusion criteria

• Any history of endometrial polyps, endometrial cancer, atypical endometrial hyperplasia, or other endometrial disorders unless subjects have undergone total hysterectomy and there is no evidence of active disease
• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
• History of any thrombophilic condition, inflammatory bowel disease, active bowel inflammation, chronic diarrhea, short bowel syndrome, and upper gastro-intestinal (GI) surgery including gastric resection
• Any history of venous thrombosis (including pulmonary embolism [PE])
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 90 days prior to Check-in (Day -1) in Period 1
• Use of systemic hormone replacement therapy within 1 year prior to Check-in (Day -1)
• History of use of tamoxifen, aromatase inhibitors, or any other endocrine agent for the treatment of breast cancer